The only approved GA treatment with 3 years of continuous trial data^1-5

Quick links:
Trial Designs
OAKS and DERBY Baseline

Of approved GA treatments,

SYFOVRE is the only GA treatment with 3 years of continuous trial data^1-5

Longest continuously enrolled GA programs^1-5

2-year Phase 3 trials & ongoing 3-year extension trial ^1,2

Largest enrollment^1,3-5

>1200 patients¹*

Most injections^6,7

>18,000 injections^2†

Reflective of GA patients who may be seen in real-world clinical practice²

Lesions with and without subfoveal involvement^‡
With and without history of or active CNV in the fellow eye
Unilateral and bilateral GA
Unifocal and multifocal lesions
Broad range of lesion sizes (2.5 mm² to 17.5 mm²)

*1258 patients randomized among SYFOVRE and sham treatment groups in OAKS and DERBY.^2,8

^†18,025 SYFOVRE injections administered across 1111 patients randomized among monthly and EOM treatment groups in OAKS and DERBY, and through 1 year of GALE, including patients who crossed over to monthly or EOM treatment from sham.¹

^‡Lesions without subfoveal involvement defined as distance >0 µm from the atrophy junction to the foveal center.²

Scroll to see full chart → Scroll to see more

Two Phase 3 trials and an ongoing extension trial evaluated the efficacy and safety of SYFOVRE^1,2

OAKS and DERBY 2‑year,
double-masked trials^1,2

TRIAL ASSESSMENT:

Change from baseline in rate of GA lesion area growth measured by FAF

Explore OAKS and DERBY efficacy results >

PATIENTS WITH GA SECONDARY TO AMD (N=1258)¹

Randomized 2:2:1:1

83% OF PATIENTS WHO COMPLETED OAKS OR DERBY CONTINUED IN GALE^§ (N=780)^||

SYFOVRE
MONTHLY
(n=419)

SYFOVRE
EOM
(n=420)

SHAM
MONTHLY
(n=208)

SHAM
EOM
(n=211)

Sham groups pooled for analysis (n=419)

GALE 3-year, open-label, extension trial²

TRIAL ASSESSMENTS:

Incidence and severity of ocular and systemic adverse events (AEs)
Change from baseline in the total area of GA lesion(s) in study eye (mm²)

Explore GALE efficacy results >

SYFOVRE
MONTHLY
(n=241)

SYFOVRE
EOM
(n=267)

CONTINUED TREATMENT

SYFOVRE
MONTHLY
(n=129)

SYFOVRE
EOM
(n=143)

PREVIOUSLY UNTREATED

1-YEAR ANALYSIS

92% patient retention in the first year of GALE²

^§First GALE visit was required to be within 60 days of the final OAKS and DERBY visit.²

^‖Ten patients from Phase 1b Study 103 enrolled in GALE and are included in the safety analysis.²

GALE is an ongoing open-label, multi-center extension study, subject to patient dropouts over time
The analysis for the first year of GALE utilized a projected sham and may not reflect rate of change of all patients with GA; projected sham assumes linear growth rate from Months 24-36 (GALE Year 1)
This is a prespecified analysis but there is no statistical testing hierarchy, therefore the results on the individual components need cautious interpretation
Open-label studies can allow for selection bias
- Of note, the 24-month lesion growth rate reduction vs sham pooled for those that continued into GALE was similar to the overall patient population from OAKS and DERBY

Baseline demographics and study eye characteristics²

Scroll to see full chart →

SYFOVRE® (pegcetacoplan injection) OAKS and DERBY baseline characteristics icon

Baseline Patient Characteristics

OAKS

SYFOVRE
MONTHLY
(n=202)

SYFOVRE
EOM
(n=205)

SHAM
POOLED
(n=207)

DERBY

SYFOVRE
MONTHLY
(n=201)

SYFOVRE
EOM
(n=201)

SHAM
POOLED
(n=195)

PATIENT CHARACTERISTICS

Mean age (years)

Female

62%

57%

64%

59%

60%

63%

Male

38%

43%

36%

41%

40%

37%

Caucasian

92%

91%

93%

96%

Fellow eye CNV

21%

18%

21%

19%

20%

19%

GEOGRAPHIC REGION

73%

69%

72%

71%

61%

63%

ROW

27%

31%

29%

39%

37%

STUDY EYE CHARACTERISTICS

Mean GA lesion size

8.2 mm²

8.3 mm²

8.2 mm²

8.4 mm²

8.3 mm²

8.2 mm²

GA lesion size <7.5 mm²

50%

48%

50%

49%

GA lesion location without subfoveal involvement

43%

36%

29%

36%

40%

37%

GA lesion focality unifocal

29%

30%

33%

27%

26%

34%

Bilateral GA

83%

85%

80%

82%

80%

77%

Number of intermediate/large drusen >20

46%

51%

50%

39%

50%

Pseudodrusen (NIR)

83%

87%

84%

89%

90%

85%

Mean BCVA score

Mean LLD*—ETDRS letters

A broad range of patients were included²

Key inclusion criteria

GA lesion requirements:
- Total size: 2.5 mm² to 17.5 mm²
- With and without subfoveal lesion involvement
- If multifocal, at least 1 focal lesion must be ≥1.25 mm²
- Presence of perilesional hyperautofluorescence
Age ≥60 years
BCVA ≥24 letters using ETDRS charts in the study eye

Key exclusion criteria

GA secondary to a condition other than AMD such as Stargardt disease in either eye
History of or active CNV in the study eye, including presence of RPE rips (assessed by reading center)
Prior participation in any other interventional clinical study for GA in either eye

Either GA, CNV, or both were permitted in the fellow eye²

*LLD at baseline was available for 199, 199, and 192 patients in the monthly, EOM, and sham groups, respectively, in DERBY.²

OAKS and DERBY

In OAKS, 31% of patients in the monthly group, 21% of patients in the every other month and 25% of the patients assigned to sham discontinued treatment prior to Year 2. In DERBY, 29% of patients in the monthly group, 22% of patients in the every other month and 21% of the patients assigned to sham discontinued treatment prior to Year 2.¹

The most frequent reasons for discontinuation from treatment were consent withdrawal (10%), death (4%), adverse events (4%), and COVID-19 impact (4%).²

Among all patients enrolled in OAKS and DERBY who received at least one injection of SYFOVRE or sham, 75% completed their respective study through Year 2 (n=940/1256).²

GALE

In GALE, 6.4% of patients in the continued monthly group, 9.3% of patients in the continued EOM group, 10.9% in sham monthly to SYFOVRE monthly group, and 5.6% of patients in the sham EOM to SYFOVRE EOM group discontinued treatment prior to Year 3.²

The most frequent reasons for discontinuation from treatment were consent withdrawal (3.3%), death (2.7%), and adverse events (1.4%).²

The only approved GA treatment to include EOM dosing from the start of clinical trials^1,4

AMD=age-related macular degeneration; BCVA=best-corrected visual acuity; CNV=choroidal neovascularization; EOM=every other month; ETDRS=Early Treatment Diabetic Retinopathy Study; FAF=fundus autofluorescence; GA=geographic atrophy; LLD=low-luminance deficit; RPE=retinal pigment epithelium; ROW=rest of world.

Back
How SYFOVRE works

Next
SYFOVRE Dosing and Administration

References: 1. SYFOVRE (pegcetacoplan injection) [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2023. 2. Data on file. Apellis Pharmaceuticals, Inc. 3. Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128(4):576-586. doi:10.1016/j.ophtha.2020.08.027. 4. A phase 3 safety and efficacy study of intravitreal administration of zimura (complement C5 inhibitor). ClinicalTrials.gov identifier: NCT04435366. Updated March 27, 2023. Accessed June 22, 2023. https://classic.clinicaltrials.gov/ct2/show/NCT04435366. 5. Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666-677. doi:10.1001/ jamaophthalmol.2018.1544. 6. US Food and Drug Administration. Center for Drug Evaluation and Research. Application Number 217171Orig1s000 Summary Review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217171Orig1s000SumR.pdf. Accessed 2/2024. 7. US Food and Drug Administration. Center for Drug Evaluation and Research. Application Number 217225Orig1s000 Summary Review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000SumR.pdf. Accessed 2/2024. 8. Fernández EJ, Villa-Carpes JA, Martinez-Ojeda RM, Ávila FJ, Bueno JM. Retinal and choroidal thickness in myopic young adults. Photonics. 2022;9(5):328. doi:10.3390/photonics9050328.

The only approved GA treatment with 3 years of continuous trial data^1-5

Of approved GA treatments,

SYFOVRE is the only GA treatment with 3 years of continuous trial data^1-5

Reflective of GA patients who may be seen in real-world clinical practice²

Two Phase 3 trials and an ongoing extension trial evaluated the efficacy and safety of SYFOVRE^1,2

Baseline demographics and study eye characteristics²

Baseline Patient Characteristics

A broad range of patients were included²

Key inclusion criteria

Key exclusion criteria

Either GA, CNV, or both were permitted in the fellow eye²

OAKS and DERBY

GALE

ADDITIONAL nAMD INFORMATION^1,2

RATES OF IOI AND IE PER INJECTION²

Use of SYFOVRE was associated with episodes of IOI. After inflammation resolves, patients may resume treatment with SYFOVRE¹

The only approved GA treatment with 3 years of continuous trial data1-5

Of approved GA treatments,

SYFOVRE is the only GA treatment with 3 years of continuous trial data1-5

Reflective of GA patients who may be seen in real-world clinical practice2

Two Phase 3 trials and an ongoing extension trial evaluated the efficacy and safety of SYFOVRE1,2

GALE: Trial limitations2

OAKS and DERBY: Baseline characteristics and inclusion criteria

Baseline demographics and study eye characteristics2

Baseline Patient Characteristics

A broad range of patients were included2

Key inclusion criteria

Key exclusion criteria

Either GA, CNV, or both were permitted in the fellow eye2

Subject disposition

OAKS and DERBY

GALE

The only approved GA treatment with 3 years of continuous trial data^1-5

SYFOVRE is the only GA treatment with 3 years of continuous trial data^1-5

Reflective of GA patients who may be seen in real-world clinical practice²

Two Phase 3 trials and an ongoing extension trial evaluated the efficacy and safety of SYFOVRE^1,2

Baseline demographics and study eye characteristics²

A broad range of patients were included²

Either GA, CNV, or both were permitted in the fellow eye²